oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 170 )

2018 ( 281 )

2017 ( 308 )

2016 ( 394 )

Custom range...

Search Results: 1 - 10 of 206240 matches for " Mark G. Martens "
All listed articles are free for downloading (OA Articles)
Page 1 /206240
Display every page Item
Patient Preferences in the Treatment of Vaginal Candidiasis  [PDF]
Mark G. Martens
Open Journal of Obstetrics and Gynecology (OJOG) , 2018, DOI: 10.4236/ojog.2018.812116
Abstract: Vulvovaginal candidiasis (VVC) is one of the most frequent problems facing women and their healthcare professionals (HCP). It is difficult for providers to understand the prevalence of VVC because effective over the counter treatments (OTC), are available. It is expected that there are a great many more episodes of VVC in our patient population, as the frequency of self-treatment, success and satisfaction for those that use OTC products prior to seeing a women’s health care provider is unknown. In this study; healthcare providers were given OTC miconazole/tioconazole units for free distribution to patients for whom they diagnosed VVC by exam in their offices. Surveys for both HCP and patients were also distributed to determine the initial or recurrent nature of their symptoms and their satisfaction with their treatments. 1265 OBGYNs and 1821 NP/CNM/PAs reported on over 19,000 patients receiving a single complete treatment. Among HCPs, treatment efficacy was the primary reason for recommending miconazole/tioconazole. However, rapid onset of symptom relief, safety vs. fluconazole, patient preference for the less messy ovule, avoidance with drugs metabolized by the liver, and resistance to, or failure on, fluconazole were additional reasons noted for topical preference. Overall, patient satisfaction (n =
Prevalence of Non-Albicans Candida Infections in Women with Recurrent Vulvovaginal Symptomatology  [PDF]
Jason D. Mintz, Mark G. Martens
Advances in Infectious Diseases (AID) , 2013, DOI: 10.4236/aid.2013.34035
Abstract:

Background: Candida vulvovaginitis is one of the most frequently diagnosed conditions in women’s care practices. Historically, 90% of cultured yeast species were C. albicans. However, due to a variety of interventions, the proportion of non-albicans Candida (NAC) infections appears to be increasing. We sought to estimate the current prevalence of Candida vulvovaginitis and the species-specific distribution of such infections in recurrent cases. Methods: Women with recurrent vulvovaginal symptomatology referred to an Obstetrics and Gynecology practice were tested by genital fungus culture, Candida-specific polymerase chain reaction (PCR), or both between July 2010 and February 2013. Results: A total of 103 women were tested. Mean age was 45.6 years. Including only their most recent positive test result, 29.1% (30/103) of women tested positive for Candida by any of the above testing measures. Of those, 50% (15/30) tested positive for C. albicans and 50% (15/30) tested positive for a NAC species. Across all visits, 60% (18/30) tested positive for C.

Douching: A Risk to Women's Healthcare?
Mark Martens,Gilles R. G. Monif
Infectious Diseases in Obstetrics and Gynecology , 2003, DOI: 10.1080/10647440300025511
Abstract:
Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes
Mark G. Martens,Kenneth H. Fife,Peter A. Leone,Lynn P. Dix,Clare A. Brennan
Infectious Diseases in Obstetrics and Gynecology , 2009, DOI: 10.1155/2009/105376
Abstract: Objective. Genital herpes (GH) recurrences and viral shedding are more frequent in the first year after initial HSV-2 infection. The objective of this study was to provide the first evaluation of valacyclovir 1 g once daily compared to placebo in reducing viral shedding in subjects newly diagnosed with GH. Methods. 70 subjects were randomized to receive valacyclovir 1 g daily or placebo in a crossover design for 60 days with a 7-day washout period. A daily swab of the genital/anal-rectal area was self-collected for HSV-2 detection by PCR. Subjects attended the clinic for routine study visits and GH recurrence visits. Treatment differences were assessed using a nonparametric crossover analysis. Results. 52 subjects had at least one PCR measurement in both treatment periods and comprised the primary efficacy population. Valacyclovir significantly reduced HSV-2 shedding during all days compared to placebo (mean 2.9% versus 13.5% of all days (<.01), a 78% reduction). Valacyclovir significantly reduced subclinical HSV-2 shedding during all days compared to placebo (mean 2.4% versus 11.0% of all days (<.01), a 78% reduction). However, 79% of subjects had no GH recurrences while receiving valacyclovir compared to 52% of subjects receiving placebo (<.01). Conclusion. In this study, the frequency of total and subclinical HSV-2 shedding was greater than reported in earlier studies involving subjects with a history of symptomatic genital recurrences. Our study is the first to demonstrate a significant reduction in viral shedding with valacyclovir 1 g daily compared to placebo in a population of subjects newly diagnosed with HSV-2 infection.
Quick Minds Slowed Down: Effects of Rotation and Stimulus Category on the Attentional Blink
Sander Martens,Ozlem Korucuoglu,Henderikus G. O. M. Smid,Mark R. Nieuwenstein
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0013509
Abstract: Most people show a remarkable deficit to report the second of two targets when presented in close temporal succession, reflecting an attentional restriction known as the ‘attentional blink’ (AB). However, there are large individual differences in the magnitude of the effect, with some people showing no such attentional restrictions.
Travel in Pregnancy: The Impact of Zika  [PDF]
Erin E. Curcio, Jonathan D. Baum, Debra Gussman, Mark Martens
Open Journal of Obstetrics and Gynecology (OJOG) , 2017, DOI: 10.4236/ojog.2017.710107
Abstract: OBJECTIVE: The purpose of our study was to examine current travel patterns and behaviors of pregnant women. METHODS: We developed a questionnaire adapted from a publication by Kingman and Economides to examine the travel behavior of women during pregnancy in a suburban community. RESULTS: A convenience sample of 102 patients completed the travel questionnaire. Forty-six (45.1%) traveled during the current pregnancy. Thirty-one (30.4%) traveled more than once. A total of 257 trips were taken by the participants: 113 (43.9%) trips were taken in the first trimester, 87 (33.8%) in the second and 59 (22.9%) in the third trimester. Trip length ranged from 2-90 days with a mean of 11 days. Reasons for travel included: 193 (75.1%) for leisure, 37 (14.4%) work related, 10 (3.9%) trips for emergencies, and 3 (0.4%) trips for relocation.?Eighteen women (17.6%) traveled internationally. One (1.0%) woman was hospitalized while traveling. Manner of travel was as follows: car 167 (65.0%), plane 67 (26.1%), train 13 (5.1) %, bus 10 (3.9%) and none by boat. Nineteen (41.3%) women sought travel advice. Thirteen (68.4%) asked for advice from a doctor, 2 (10.5%) from a nurse, 2 (10.5%) from family and/or friends, 1 (5.3%) from the Internet and 1 (5.3%) from a travel book. Seventeen (37%), traveled without suitable insurance. DISCUSSION: Travel rates during pregnancy have remained surprisingly stable over the past 60 years. Almost 50% of our cohort traveled during pregnancy, and the majority did not seek advice prior to travel. In light of new infectious disease threats, obstetric practice and advice needs reassessment. The majority of travel during pregnancy remains optional. Improved patient education and consultations prior to travel could decrease health risks.
On the gonality sequence of an algebraic curve
H. Lange,G. Martens
Mathematics , 2010,
Abstract: For any smooth irreducible projective curve $X$, the gonality sequence $\{d_r \;| \; r \in \mathbb N \}$ is a strictly increasing sequence of positive integer invariants of $X$. In most known cases $d_{r+1}$ is not much bigger than $d_r$. In our terminology this means the numbers $d_r$ satisfy the slope inequality. It is the aim of this paper to study cases when this is not true. We give examples for this of extremal curves in $\PP^r$, for curves on a general K3-surface in $\PP^r$ and for complete intersections in $\PP^3$.
Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled Studies
David A. Baker,Daron G. Ferris,Mark G. Martens,Kenneth H. Fife,Stephen K. Tyring,Libby Edwards,Anita Nelson,Kevin Ault,Kenneth F. Trofatter,Tiepu Liu,Sharon Levy,Jason Wu
Infectious Diseases in Obstetrics and Gynecology , 2011, DOI: 10.1155/2011/806105
Abstract: Objective. To evaluate if new imiquimod formulations using a shorter treatment duration are safe and efficacious to treat anogenital warts. Methods. In two studies 534 women ≥12 years of age (mean 33.4) with 2–30 warts (mean 7.9) and total wart area ?mm2 (mean 166.3) were randomized (1?:?2?:?2) to placebo (106), imiquimod 2.5% (212) or 3.75% (216) creams applied once daily until complete clearance or a maximum of 8 weeks. Results. For placebo, imiquimod 2.5% and 3.75%, respectively, complete clearance of all warts was achieved in 14.2%, 28.3%, and 36.6% of women (intent-to-treat, imiquimod 2.5%, and 3.75% versus placebo). Mean changes in wart counts were ?10.7%, ?50.9%, and ?63.5% (per-protocol, each active versus placebo) and safety-related discontinuation rates 0.9%, 1.4%, and 2.3%. Conclusions. Imiquimod 3.75% applied daily for up to 8 weeks was well tolerated and superior to placebo in treating women with external anogenital warts. 1. Introduction Human papillomavirus (HPV) infection is the most frequent sexually transmitted disease in the United States [1]. The major clinical focus in women with HPV has been on the prevention of cervical cancer, predominantly associated with oncogenic HPV types such as 16 and 18, through screening, and, more recently, through HPV vaccination [2]. External (ano)genital warts (EGW), however, are also a common manifestation of??HPV infection, usually associated with HPV types 6 and 11, types not included in one of the two marketed vaccines [3]. EGWs are frequently multicentric and recurrent. The estimated prevalence of EGWs in the sexually active population between 15 and 49 years of age in the United States is 1% [4]. Up to 7.2% of women report a history of EGWs [5]. A significant detrimental impact on quality of life was observed in adults with a current diagnosis of EGWs, particularly in young women [6]. In a study assessing the psychosocial burden of HPV-related disease, women with EGWs reported lower general quality of life scores than women with abnormal Papanicolaou smears or biopsy-proven cervical intraepithelial neoplasia [7]. With an HPV-specific impact profile instrument, the impact on quality of life of having EGWs was second to that of having cervical intraepithelial neoplasia 2/3 [7]. EGWs also represent a significant burden to the health care system with an estimated 385,000 initial visits to physician offices in 2008 [8] and $200 million in direct costs annually in the United States [9]. Treatments for EGWs focus on the removal of visible warts [3] and can be divided broadly into two categories:
Prelabour Caesarean Section following IVF/ICSI in Older-Term Nulliparous Women: Too Precious to Push?
E. Gillet,E. Martens,G. Martens,H. Cammu
Journal of Pregnancy , 2011, DOI: 10.1155/2011/362518
Abstract: Objective. To compare prelabour caesarean section (CS) rates in older nulliparous women with a term singleton baby in cephalic presentation conceiving spontaneously and through IVF/ICSI. When the latter women would ask for CS, how willing are gynaecologists to comply with that request? Methods. A population-based retrospective (1995–2009) cohort study, conducted in Northern Belgium. A comparison of 1,866 nulliparous women pregnant after IVF/ICSI and 15,228 controls is made. An anonymous postal questionnaire is sent to all Belgian gynaecologists. Result. Both groups are comparable with respect to maternal age, gestational age, and birth weight. Prelabour CS is more often performed in women who conceived through IVF/ICSI compared to those who conceived spontaneously (9.2% versus 6.3%, ). One in five gynaecologists agrees with the maternal request. Conclusion. IVF/ICSI pregnancies in older nulliparous women more often end in a prelabour CS and a substantial number of gynaecologists go along with a nonmedical reason for CS. 1. Introduction Caesarean sections (CSs) now exceed rates thought capable of delivering health benefits to mothers and babies [1]. Indications to perform this major operation have changed over the past decade [2]. Caesarean delivery on maternal request (CDMR) has been added to this list of indications and considered an important contributing factor in the CS rising rate [3–5]. The latter occurs when a woman asks to schedule a purely planned caesarean section on a date mutually convenient for her and her doctor, before the onset of labour, without any medical rationale, and in the absence of any clinical indication. Women’s preference can be affected by tokophobia (fear of childbirth), the risk of out-of-hour delivery, the belief that caesareans are safest for the baby, or because vaginal delivery has become stigmatised as archaic and disfiguring [6]. However, in a review of the literature on women’s request for caesarean section, it turned out that few women request this procedure in the absence of current or previous obstetric complications [7, 8]. A growing number of women achieve their first pregnancy late in life [9–11]. In Flanders, from 1995 until 2010 the percentage of primiparous women being 35 years or older increased from 3.6% to 8.3% (SPE, annual reports). Fertility decreases with age. Consequently, older women will make more use of assisted reproductive technologies (ART). Babies, conceived after ART, of older primiparous women may therefore be considered as “Precious Babies” [12]. The aim of this study is to find out whether
Participant characteristics associated with withdrawal from a large randomized trial of spermicide effectiveness
Elizabeth G Raymond, Pai Chen, Bosny Pierre-Louis, Joanne Luoto, Kurt T Barnhart, Lynn Bradley, Mitchell D Creinin, Alfred Poindexter, Livia Wan, Mark Martens, Robert Schenken, Cate F Nicholas, Richard Blackwell
BMC Medical Research Methodology , 2004, DOI: 10.1186/1471-2288-4-23
Abstract: Trial participants were expected to use the assigned spermicide for contraception for 7 months or until pregnancy occurred. In bivariable and multivariable analyses, we assessed the associations between failure to complete the trial and 17 pre-specified baseline characteristics. In addition, among women who participated for at least 6 weeks, we evaluated the relationships between failure to complete, various features of their first 6 weeks of experience with the spermicide, and characteristics of the study centers and population.Of the 1514 participants in this analysis, 635 (42%) failed to complete the study for reasons other than pregnancy. Women were significantly less likely to complete if they were younger or unmarried, had intercourse at least 8 times per month, or were enrolled at a university center or at a center that enrolled fewer than 4 participants per month. Noncompliance with study procedures in the first 6 weeks was also associated with subsequent early withdrawal, but dissatisfaction with the spermicide was not. However, many participants without these risk factors withdrew early.Failure to complete is a major problem in barrier method trials that seriously compromises the interpretation of results. Targeting retention efforts at women at high risk for early withdrawal is not likely to address the problem sufficiently.Retention of participants has been a consistent problem in clinical studies of barrier contraceptive methods. For example, in six large studies of condoms, diaphragms, and spermicides conducted in the past decade, more than 30% of the participants failed for reasons other than pregnancy to complete the intended six months or six menstrual cycles of follow-up [1-6] Such high dropout rates seriously compromise the interpretation of trial results.Issues regarding the design of barrier method studies have become increasingly important to researchers and public health scientists since the onset of the HIV epidemic because of the urgent need
Page 1 /206240
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.